Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

Figure 1

A/J strain Tsc2+/- mice show an increased severity of kidney disease with age, a greater kidney tumor burden than C57BL/6 Tsc2+/- mice, and best response to longer duration rapamycin treatment. The average score per kidney for each cohort is shown in 1a. The average number of cystadenomas per kidney for each cohort is shown in 1b. The red p-values indicate a statistically significant difference (p < 0.05) between the two cohorts being compared. These data show a significant increase in both the score per kidney and the number of cystadenomas per kidney in the A/J strain as compared to the C57BL/6 strain for both 9 months of age and 12 months of age. Additionally, these data show a significant increase with age in both the score per kidney and the number of cystadenomas per kidney for the A/J Tsc2+/- strain. Furthermore, the tumor burden is reduced with rapamycin therapy with the weekly × 12 weeks cohort and the daily × 4 weeks plus weekly × 8 weeks cohort showing the most reduction. This data is summarized in Table 1.

Back to article page